Dihydroergotamine: Discrepancy between arterial, arteriolar and pharmacokinetic data

British Journal of Clinical Pharmacology

Volumn 52, Issue 1, 2001, Pages 45-51

  De Hoon, Jan N J M ^a,b   Poppe, K A ^a   Thijssen, H H W ^a   Struijker Boudier, H A J ^a   Van Bortel, L M A B ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Arterial; Arteriolar; Dihydroergotamine; Pharmacokinetics human

Indexed keywords

DIHYDROERGOTAMINE MESILATE; PLACEBO;

ADULT; ARTERY COMPLIANCE; ARTERY DIAMETER; ARTERY RESISTANCE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL WALL; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FOREARM BLOOD FLOW; HEART RATE; HUMAN; MALE; NORMAL HUMAN; OSCILLOMETRY; PRIORITY JOURNAL; TONOMETRY; ULTRASOUND; VASOCONSTRICTION; VEIN OCCLUSION PLETHYSMOGRAPHY; VENOUS BLOOD;

EID: 0034818679     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01415.x     Document Type: Article

References (26)

1. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus
2. The pharmacology of ergotamine and dihydroergotamine
3. Actions on the heart and circulation
4. What is known about the action of dihydroergotamine on the vasculature in man?
5. Ex vivo studies after oral treatment of the beagle with dihydroergotamine
6. A new technique for recording compliance of human hand veins
7. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing
8. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration
9. Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery
10. Coronary side-effect potential of current and prospective antimigraine drugs
11. Intramuscular ergotamine: Plasma levels and dynamic activity
12. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man
13. Assessment of the distensibility of superficial arteries
14. Noninvasive registration of the arterial pressure pulse waveform using high-fidelity applanation tonometry
15. Measuring forearm blood flow and interpreting the responses to drugs and mediators
16. 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls
17. Non-invasive assessment of pulse pressure at different peripheral arteries in man
18. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans
19. Practice parameter: Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Summary statement
20. Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation
21. Pharmacokinetic investigation of oral and iv dihydroergotamine in healthy subjects
22. Human pharmacokinetics of dihydroergotamine by nasal spray
23. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers
24. Pharmacological actions of the main metabolites of dihydroergotamine
25. Reduced distensibility of the common carotid artery in patients treated with ergotamine
26. 1B/1D-receptor agonists in patients with migraine headaches